Related Experiment Video
Updated: Mar 2, 2026
14:32
Deacetylation Assays to Unravel the Interplay between Sirtuins SIRT2 and Specific Protein-substrates
Published on: February 27, 2016
8.7K
Sirt1 ameliorates systemic sclerosis by targeting the mTOR pathway
Xiaoxia Zhu1, Haiyan Chu2, Shuai Jiang2
1Division of Rheumatology, Huashan Hospital, Fudan University, China; Institute of Rheumatology, Immunology and Allergy, Fudan University, China.
Journal of Dermatological Science
|May 24, 2017
Summary
Sirtuin1 (Sirt1) activation, using resveratrol, reduces inflammation and fibrosis in systemic sclerosis (SSc) by inhibiting mammalian target of rapamycin (mTOR). This suggests Sirt1 modulation as a potential therapy for SSc.
Area of Science:
- Immunology
- Autoimmune Diseases
- Fibrosis Research
Background:
- Systemic sclerosis (SSc) is a chronic autoimmune condition marked by inflammation and fibrosis.
- Previous studies linked Sirtuin1 (Sirt1) to TNF-α-induced inflammation, but its role in inhibiting SSc progression was unclear.
Purpose of the Study:
- To investigate the function and mechanism of Sirt1 in systemic sclerosis (SSc).
Main Methods:
- Sirt1 function and mechanism were assessed in SSc patient fibroblasts and bleomycin-induced scleroderma mouse models.
- Expression levels of Sirt1, cytokines, and mammalian target of rapamycin (mTOR) were quantified using real-time PCR, western blot, ELISA, and immunohistochemistry.
Main Results:
- Activated Sirt1, via resveratrol, alleviated inflammation and fibrosis in scleroderma mouse models.
- Resveratrol treatment inhibited mTOR expression and activity, reducing inflammation and fibrosis in SSc fibroblasts and mouse models.
- mTOR inhibition, using rapamycin or knockdown, also reduced SSc-related inflammation and fibrosis.
Conclusions:
- Sirt1 modulation shows potential as a therapeutic strategy for systemic sclerosis (SSc).
- The mechanism involves inhibiting mTOR phosphorylation, identifying mTOR as a key pathogenic factor in SSc.
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
4.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.9K
01:20The JAK-STAT Signaling Pathway
13.4K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
13.4K
01:22PI3K/mTOR/AKT Signaling Pathway
5.9K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.9K
01:22iPS Cell Differentiation
3.2K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
3.2K
01:21Satellite Stem Cells and Muscular Dystrophy
2.5K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.5K